Estimating Drug Efficacy with a Diet-Induced NASH Model in Chimeric Mice with Humanized Livers
Open Access
- 9 November 2021
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 9 (11) , 1647
Abstract
Nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) is the most common liver disorder in developed countries. Although many new therapeutics for NASH are present in the drug development pipeline, there are still no approved drugs. One of the reasons that makes NASH drug development challenging is the lack of appropriate animal NASH models that resolve issues arising from inter-species differences between humans and rodents. In the present study, we developed a choline-deficient, L-amino-acid-defined, high-fat-diet (CDAHFD)-induced human NASH model using human liver chimeric mice. We demonstrated human hepatocyte injury by an elevation of plasma human alanine aminotransferase 1 in mice fed CDAHFD. Histological analysis showed that CDAHFD feeding induced similar histological changes to human NASH patients, including ballooning, inflammation, apoptosis, regeneration of human hepatocytes, and pericellular and perisinusoidal fibrosis. The chimeric mice fed CDAHFD were treated with a peroxisome-proliferator-activated receptor α/δ agonist, Elafibranor. Elafibranor ameliorated steatosis, ballooning of hepatocytes, and preserved fibrosis progression. We developed a novel humanized NASH model that can elucidate pathophysiological mechanisms and predict therapeutic efficacy in human NASH. This model will be useful in exploring new drugs and biomarkers in the early stages of human NASH.Keywords
This publication has 54 references indexed in Scilit:
- Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic SteatohepatitisInternational Journal of Molecular Sciences, 2013
- An improved mouse model that rapidly develops fibrosis in non‐alcoholic steatohepatitisInternational Journal of Experimental Pathology, 2013
- Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonistProceedings of the National Academy of Sciences, 2012
- Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose MetabolismDiabetes Care, 2011
- Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implicationsExpert Review of Gastroenterology & Hepatology, 2011
- Hepatic Hyperplasia Associated with Discordant Xenogeneic Parenchymal-Nonparenchymal Interactions in Human Hepatocyte-Repopulated MiceThe American Journal of Pathology, 2010
- Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and HumanPLOS ONE, 2009
- Orlistat for overweight subjects with nonalcoholic steatohepatitisHepatology, 2009
- The Role of PPARs in CancerPPAR Research, 2008
- Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the LiverPhysiological Reviews, 2008